TA Patients, n = 45 | Controls, n = 47 | p | |
---|---|---|---|
Glucose, mg/dl | 86.84 ± 23.99 | 80.98 ± 28.92 | 0.294 |
Total cholesterol, mg/dl | 189.06 ± 44.89 | 194.00 ± 41.14 | 0.583 |
LDL-C, mg/dl | 113.14 ± 40.59 | 117.93 ± 30.53 | 0.523 |
HDL-C, mg/dl | 55.04 ± 15.71 | 57.27 ± 18.66 | 0.538 |
TG, mg/dl | 105.74 ± 63.43 | 93.02 ± 44.23 | 0.266 |
Insulin, mU/ml | 11.02 ± 11.68 | 6.74 ± 4.24 | 0.021 |
HOMA-IR | 2.41 ± 2.65 | 1.43 ± 1.21 | 0.024 |
HOMA-IR > 3.4, n | 9 (20) | 4 (8.51) | 0.114 |
apoA1, mg/dl | 146.02 ± 28.87 | 153.21 ± 40.22 | 0.329 |
apoA2, mg/dl | 34.28 ± 18.12 | 36.32 ± 11.25 | 0.516 |
apoB, mg/dl | 84.95 ± 32.67 | 85.86 ± 21.74 | 0.875 |
apoE, mg/dl | 4.56 ± 1.38 | 3.95 ± 1.26 | 0.029 |
Lipoprotein A, mg/dl | 52.93 ± 70.04 | 39.70 ± 40.84 | 0.313 |
CRP, mg/dl | 9.88 ± 11.71 | 2.77 ± 2.17 | < 0.001 |
ESR, mm | 18.34 ± 20.10 | 5.82 ± 3.41 | < 0.001 |
Creatinine, mg/dl | 0.77 ± 0.16 | 0.72 ± 0.12 | 0.092 |
Adiponectin, μg/ml | 33.16 ± 23.21 | 40.54 ± 50.98 | 0.417 |
Resistin, ng/ml | 22.55 ± 12.62 | 15.94 ± 10.11 | 0.018 |
PAI-1, ng/ml | 51.71 ± 23.80 | 42.38 ± 17.83 | 0.128 |
IL-12, pg/ml | 4.11 ± 8.89 | 3.33 ± 32.90 | 0.781 |
IL-1a, pg/ml | 7.43 ± 11.03 | 9.66 ± 29.87 | 0.448 |
IL-6, pg/ml | 9.32 ± 3.70 | 1.47 ± 4.94 | 0.108 |
TNF-α, pg/ml | 4.71 ± 7.07 | 19.19 ± 4.03 | 0.581 |
Data are mean ± SD or percentage. LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostatic model assessment of insulin resistance; apo: apolipoprotein; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; PAI-1: plasminogen activator inhibitor-1; IL: interleukin; TNF-α: tumor necrosis factor-α; TG: triglycerides.